$84.85
0.58% yesterday
Nasdaq, Nov 28, 07:00 pm CET

ANI Pharmaceuticals, Inc. Stock price

$84.85
-8.44 9.05% 1M
+27.04 46.77% 6M
+29.57 53.49% YTD
+25.46 42.87% 1Y
+44.84 112.07% 3Y
+55.29 187.04% 5Y
+41.03 93.63% 10Y
-69.95 45.19% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.49 0.58%

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$2.2b
Net debt
$348.8m
Cash
$271.5m
Shares outstanding
22.5m
Valuation (TTM | estimate)
P/E
51.8 | 11.4
P/S
2.3 | 2.2
EV/Sales
2.7 | 2.6
EV/FCF
14.4
P/B
3.8
Financial Health
Equity Ratio
33.4%
Return on Equity
-4.7%
ROCE
7.1%
ROIC
6.4%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$826.9m | $861.6m
EBITDA
$172.0m | $224.4m
EBIT
$80.6m | $224.4m
Net Income
$34.1m | $166.9m
Free Cash Flow
$155.7m
Growth (TTM | estimate)
Revenue
19.3% | 40.2%
EBITDA
78.6% | 218.0%
EBIT
278.3% | 7,799.7%
Net Income
352.8% | 928.2%
Free Cash Flow
102.8%
Margin (TTM | estimate)
Gross
61.1%
EBITDA
20.8% | 26.0%
EBIT
9.8%
Net
4.1% | 19.4%
Free Cash Flow
18.8%
More
EPS
$1.6
FCF per Share
$6.9
Short interest
13.8%
Employees
897
Rev per Employee
$680.0k
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
827 827
19% 19%
100%
- Direct Costs 321 321
18% 18%
39%
506 506
20% 20%
61%
- Selling and Administrative Expenses 305 305
12% 12%
37%
- Research and Development Expense 56 56
16% 16%
7%
172 172
79% 79%
21%
- Depreciation and Amortization 91 91
22% 22%
11%
EBIT (Operating Income) EBIT 81 81
278% 278%
10%
Net Profit 34 34
353% 353%
4%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET.
Neutral
GlobeNewsWire
17 days ago
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, at 3:00 p.m.
Neutral
Seeking Alpha
21 days ago
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division David Amsellem - P...
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 897
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today